Latest Breaking News On - Inflarx gmb - Page 2 : comparemela.com

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

/PRNewswire/ WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the.

United statesChris chenInflarx gmbNielsc riedemannManufacturing organizationInflarx pharmaceuticals incContract researchWuxi biologicsInflarx pharmaceuticalsAnn arbor

InflaRx N : These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N V and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc , Ann Arbor, Michigan, United States (together, the Group ) The financial statements are presented in Euro (€) - Form 6-K

These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena,. | May 11, 2023

United statesNoord hollandAnn arborInflarx gmbCompany or inflarxArticles of association the companyPublic health emergencyDrug administrationNetherlands chamberCompany the board of directors onInflarx pharmaceuticals incInflarx gmbhCondensed consolidated statementsComprehensive lossFinancial positionShareholder equity

InflaRx N V : InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

JENA, Germany, April 14, 2023 (GLOBE NEWSWIRE) InflaRx N.V. (Nasdaq: IFRX) (the "Company"), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement

Sankt peterburgUnited statesRegina lutzInflarx gmbKatja arnoldLaurie doyleDrug administrationLifesci capitalRaymond james associates incEuropean medicines agencyMc servicesInflarx pharmaceuticals incExchange commissionEquity syndicateRaymond jamesInflarx pharmaceuticals

InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

JENA, Germany, April 14, 2023 InflaRx N.V. , a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has. | April 14, 2023

United statesSankt peterburgRegina lutzKatja arnoldInflarx gmbLaurie doyleRaymond james associates incEuropean medicines agencyLifesci capitalInflarx pharmaceuticals incGlobenewswire incExchange commissionEquity syndicateMc servicesDrug administrationSci capital

InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares

InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSankt peterburgLaurie doyleInflarx gmbRegina lutzemailInflarxn vemailRaymond james associates incMc services agkatja arnoldExchange commissionInflarx pharmaceuticals incLifesci capitalDrug administrationEuropean medicines agencyEquity syndicateWall streetRaymond james